Perseus Proteomics Inc. (TYO:4882)

Japan flag Japan · Delayed Price · Currency is JPY
233.00
+4.00 (1.75%)
Mar 6, 2026, 3:30 PM JST
-64.86%
Market Cap 3.44B
Revenue (ttm) 140.41M
Net Income (ttm) -758.12M
Shares Out 14.75M
EPS (ttm) -51.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 235,200
Average Volume 199,835
Open 226.00
Previous Close 229.00
Day's Range 220.00 - 234.00
52-Week Range 203.00 - 1,113.00
Beta 0.38
RSI 49.64
Earnings Date Feb 13, 2026

About Perseus Proteomics

Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell;... [Read more]

Sector Healthcare
Founded 2001
Employees 32
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4882
Full Company Profile

Financial Performance

In fiscal year 2025, Perseus Proteomics's revenue was 120.00 million, an increase of 20.00% compared to the previous year's 100.00 million. Losses were -904.00 million, -18.12% less than in 2024.

Financial Statements

News

There is no news available yet.